Lexaria Bioscience Corp., a leader in drug delivery platform innovation, has announced the granting of two new international patents, elevating its global patent portfolio to 50. This achievement underscores the company's strategic expansion in intellectual property, particularly in the pharmaceutical and nicotine delivery sectors. The new patents include one in Australia for epilepsy treatment and another in Japan for sublingual nicotine delivery, both utilizing Lexaria's DehydraTECH™ technology.
Rich Christopher, CEO of Lexaria, highlighted the significance of this milestone, noting its potential to foster commercial partnerships in the pharmaceutical industry and enhance shareholder value. The epilepsy treatment patent in Australia extends Lexaria's intellectual property protection outside the USA, where it already holds six patents, with expiration set for 2044. Similarly, the nicotine delivery patent in Japan complements existing patents in the USA and Canada, expiring in 2043.
The global implications of these patents are substantial, given the epilepsy drug market's projected growth to over $15 billion by 2032 and the oral nicotine market's expected annual growth rate of 26% until 2030. Lexaria's DehydraTECH™ technology, which improves drug absorption and delivery, positions the company at the forefront of these expanding markets. Earlier studies have demonstrated the technology's benefits in the nicotine pouch market, anticipated to reach $25.4 billion in revenue by 2030.
Lexaria's achievement reflects a decade-long commitment to innovation in drug delivery, with its DehydraTECH™ technology offering promising advancements in bio-absorption and blood-brain barrier penetration. The company's robust patent portfolio and ongoing research initiatives signal its potential to significantly impact the pharmaceutical and nicotine industries, offering improved treatment options and delivery methods for patients worldwide.
